secwatch.observer — SEC 8-K summary
======================================

Issuer:     Estrella Immunopharma, Inc. (ESLA)
CIK:        0001844417
Form:       8-K
Filed at:   2025-06-05T23:59:59+00:00
Accession:  0001213900-25-051361
Event type: other_material
Sentiment:  positive
Materiality: 0.50
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Estrella Immunopharma activates second clinical site for Phase I/II STARLIGHT-1 NHL trial
--------------------------------------------------------------------------------

- Baylor Research Institute in Dallas, TX now open for patient enrollment in STARLIGHT-1 trial.
- Trial evaluates EB103, a CD19-Redirected ARTEMIS T-cell therapy for relapsed/refractory B-cell NHL.
- Open-label, dose escalation/expansion Phase I/II study to determine Recommended Phase II Dose in adults ≥18.
- CEO Cheng Liu states partnership will accelerate development and increase patient access to EB103.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/0001213900-25-051361-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1844417/000121390025051361/ea0244733-8k_estrella.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-051361

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer